eMedicine Specialties > Pediatrics: Surgery > Transplantation
Posttransplant Lymphoproliferative Disease
Updated: Apr 22, 2008
Introduction
Posttransplant lymphoproliferative disease (PTLD) is an unusual entity that has many features of immune system malignancy. It is characterized by uncontrolled proliferation of B cells in a context of posttransplant immunosuppression. In some situations, reducing the immunosuppression can reverse this proliferation.
PTLD has emerged as a significant complication of solid organ transplantation. This entity was rarely reported until the mid 1980s, when the incidence began suddenly rising. PTLD presents significant problems for the clinician because it is difficult to predict and has high morbidity and mortality rates because of the difficulty in prevention and potential for graft loss.
Incidence
Multiple reports from single-center studies, as well as registry reports, have illustrated that the incidence of posttransplant lymphoproliferative disease (PTLD) rose throughout most of the 1990s.
Alfrey et al reported an increase in the overall incidence of PTLD from 0.7% from 1965-1988 to 1.9% from 1988-1990.1 Similarly, Ciancio et al reported only 2 cases of PTLD from 1977-1993, followed by 5 cases over the next 2 years (1993-1995).2 Data from the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS), which has been enrolling patients since 1987, showed a significant doubling of incidence density from 320 cases per 100,000 years of patient follow-up from 1987-1992 to 630 cases per 100,000 years of patient follow-up from 1992-1997.3
Some centers, particularly in the pediatric liver transplant population, have introduced prophylactic measures and have reported a reduction in the high prevalence of PTLD at their institutions.4,5 Current prevalence rates for posttransplant patients vary from 1-15%, depending on the organ transplanted and the immunosuppressive agents used. The prevalence of PTLD has been noted to be higher in patients with liver and heart transplants, in patients who have received one or more courses of anti-CD3 monoclonal antibody, and in patients whose primary immunosuppression is caused by tacrolimus (FK506).
Risk Factors
The prevalence of posttransplant lymphoproliferative disease (PTLD) is different for each transplanted organ. The highest rates are reported for the intestine (as much as 20%), thoracic organs (heart 2-10%, lung 4-8%), and liver (2-8%). Prevalence in kidney transplants is usually lower (1%), but some centers have reported prevalence as high as 10%. Prevalence in bone marrow transplantation is low (1-2%), except in patients in whom T-cell–depleted marrow is used; in these patients, rates as high as 24% are reported. In an analysis of the very large national United Network for Organ Sharing (UNOS) in the United States, the prevalence of PTLD was highest in intestinal transplants (8%), then thoracic organs (3-5%), followed by liver and kidney transplants.6 In addition, several different demographic, infectious, and immunosuppressive risk factors are associated with PTLD development.
Demographic risk factors
- Age: Prevalence is highest in the pediatric age group (age 0-18 y). According to analysis of UNOS data, the relative risk (RR) in this age group is 2.81 compared with adult recipients.6 Some reports have suggested that prevalence is even higher in patients younger than 5 years. Age may not be an independent risk factor but may depend on the likelihood of the recipient being seronegative for Epstein-Barr virus (EBV) at the time of transplant.
- Race: Data from the NAPRTCS and UNOS registries have shown a markedly higher risk in white children; the RR for Caucasian transplant recipients is 2.22 compared with other races.6
Infectious risk factors
- EBV serostatus: The single most important risk factor is the lack of previous exposure to EBV in the transplant recipient. Prevalence in EBV-seronegative recipients ranges from 23-50%, compared with 0.7-1.9% for seropositive recipients. Walker et al determined from their data on 381 adult nonrenal transplant recipients, 14 of whom developed PTLD, that the prevalence rate for seronegative recipients was 24 times higher than that for seropositive recipients.7
- Cytomegalovirus (CMV) infection: CMV has also been demonstrated to be associated with an increased risk of PTLD. Manez et al analyzed 40 adult liver transplant recipients, all of whom were seronegative for EBV.8 Of these recipients, 33% developed PTLD, and a diagnosis of CMV disease posttransplant increased the relative risk to 7.3. Walker et al7 studied the effect of primary CMV disease on PTLD by analyzing recipients who were seronegative for CMV and who received a CMV-positive allograft. In this group, the risk of PTLD was 4- to 6-fold higher.
Immunosuppression risk factors
- PTLD was extremely rare when 2-drug immunosuppression regimens (steroids and azathioprine) were in standard use. Incidence of PTLD rose with the advent of more potent immunosuppression, beginning with cyclosporine (ie, cyclosporin A [CsA]). In addition, certain specific agents have been reported to increase the risk of PTLD.
- Reports of PTLD were very rare prior to the introduction of cyclosporine. In one long-term study, the relative risk for PTLD with cyclosporine was significantly higher at 2.2.9
- Swinnen et al first reported the increased prevalence of PTLD (more than 4-fold) in recipients of cardiac transplants who received more than a 10-mg cumulative dose of Muromonab-Cd3 (OKT3).10 Walker et al reported that the use of OKT3 independently increased the risk of PTLD 5- to 6-fold in a multivariate analysis.7 In combination with the risk factors of an EBV-seronegative recipient and CMV, the prevalence rate rose by a factor of 529.
- Cox et al and Sokal et al reported that pediatric recipients of liver transplants who received FK506 had a higher prevalence of PTLD (13-20%) than those who received cyclosporine (2-3%).11,12 According to Newell et al, the combined use of OKT3 and FK506 appears to be synergistic, with the prevalence of PTLD increasing from 6% to 28%.13 Initial data from NAPRTCS also suggested a marked increase in PTLD with FK506-based initial immunosuppression for renal transplantation.3 However, more recent data suggest no increased risk. This may be related to lower levels of FK506 being deemed acceptable (8-12 ng/mL, compared with 12-15 ng/mL previously).
- Penn has commented that each drug used is associated with a learning curve, during which time increased adverse effects may be observed.14,15 Whether rates of PTLD will decrease in liver transplantation with lower FK506 levels is unclear. The Cochrane Review Group compared cyclosporine with FK506 and found no significant differences in relative risk for PTLD in a meta-analysis of 30 different prospective trials.16,17
- Studies that have examined the risk for PTLD with mycophenolate mofetil have not shown any increase in relative risk; these studies included a UNOS data analysis,18 , a case control study,19 and a NAPRTCS registry data analysis.20 However, other studies have documented an increased risk for BK virus nephropathy and CMV infection with mycophenolate use.
- Sirolimus has unique properties, including retention of anti-EBV T-cell activity in vitro. A recent study by of UNOS data revealed a decreased relative risk for malignancy (a different outcome variable from PTLD) with sirolimus use.18
- Data regarding PTLD risk with use of anti-interleukin (IL)-2R antibodies (basiliximab and daclizumab) have shown conflicting results. Bustami et al analyzed data from the Scientific Registry of Transplant Recipients (SRTR) and documented significantly increased relative risk (1.83-1.92) for PTLD with these agents.21 However, Cherikh et al, using similar source data from UNOS, suggested an insignificant 14% increase in relative risk.18 Opelz and Henderson, who represented the Collaborative Transplant Study in Europe, found no increased risk for non-Hodgkin lymphoma within a 12-month follow up period after anti-IL-2R antibody use.22 These differences may be related to different databases and different time periods of follow up.
Etiology and Pathogenesis
The pathogenesis of posttransplant lymphoproliferative disease (PTLD) is intimately linked to EBV. EBV is a lymphotrophic DNA gamma herpes virus that replicates in squamous epithelial cells of the oropharynx, uterine cervix, and male genital tract. The virus infects and immortalizes human or primate B lymphocytes that bear EBV membrane C3d receptors.
The free infectious virus can be recovered from saliva in essentially all healthy seropositive individuals. EBV is implicated in the pathogenesis of a spectrum of B-cell lymphoproliferative diseases in immunosuppressed organ transplant recipients, in immunodeficiency diseases (eg, common variable immunodeficiency, Wiskott-Aldrich syndrome, ataxia telangiectasia, severe combined immunodeficiency, acquired immunodeficiency syndrome), and in recipients of T-cell–depleted or mismatched bone marrow transplants.
EBV causes 2 types of cellular infections: (1) a productive replicative infection in which mature infectious virus particles are assembled and released, resulting in cell death (the lytic cycle), and (2) a nonproductive infection in which the virus is incorporated into and replicates with the host DNA but remains in the latent state in transformed B cells and no mature virus is produced.
Persistence of the EBV genome in the latent state in transformed B cells occurs following a primary EBV infection and results in a permanent carrier state, in which small numbers of latently infected B cells circulate in seropositive individuals. Elimination of these cells is carried out by human leukocyte antigen (HLA)-restricted, EBV-specific, cytotoxic T lymphocytes. Certain factors (eg, inhibition of anti-EBV T-cell immunity, such as that which occurs with posttransplant immunosuppression) allow latently infected cells to enter the lytic cycle. The suppression of EBV-specific CD8+ T cells also allows B-cell proliferation to go unchecked. In solid organ transplant recipients, the abnormal B cells are usually of recipient origin. In contrast, the abnormal B cells are usually of donor origin in recipients of bone marrow transplants.
According to the above paradigm, all PTLDs should represent B-cell proliferations secondary to EBV infection; however, T-cell and natural killer (NK)–cell PTLDs have also been reported. Penn estimated that 87% of all PTLDs were of B-cell origin, 13% were of T-cell origin, and 0.5% were of null cell origin.15 PTLDs not associated with EBV have also been reported. A higher proportion of late-developing PTLDs (>2 y posttransplant) are more likely to be non–B-cell related or non-EBV related. Thus, gaps are still recognized in the understanding of the pathogenesis of PTLD.
Although the EB virus can express up to 100 genes, in the posttransplant situation only 9-10 genes are expressed. The EB genome adopts an episomal configuration and expresses proteins such as BCRF1 and BARF1 that help avoid immune detection. The latent membrane proteins LMP1 and LMP2 are believed to act as oncogenes, allowing B cells to escape cell death and proliferate in uncontrolled fashion. In one study, some PTLDs demonstrated mutations in bcl-6, an intracellular protein of the bcl group of proteins that are involved in passive cell death pathways. Polymorphisms in 2 key anti-inflammatory cytokines, IL-10 and tumor growth factor (TGF)-beta, are associated with susceptibility to EBV-associated PTLD, suggesting that a shift in pro-/anti-inflammatory response is involved in the pathogenesis of PTLD.23
Classification of posttransplant lymphoproliferative disease
Two major different classification schemes for PTLD have been proposed to compare outcomes and determine prognosis: the World Health Organization (WHO) classification and the Harris classification.24 Of these 2, the WHO classification is now gaining wide acceptance. Both of these schemes are based on the following characteristics: clinical, histologic, immunologic cell typing, cytogenetic, immunoglobulin gene-rearrangement, and virologic. The different schemes identify either 3 or 4 distinct categories. The classification schemes have common features, including benign hyperplasia or mononucleosis as the mildest form, characterized by maintenance of the nodal architecture; malignant lymphoma, with all the features of malignancy, as the most severe form; and polymorphic or polyclonal proliferations (with nodal architecture destruction and local invasion) classified in the intermediate categories.
Depending on the interplay of immunosuppressive effect and B-cell proliferation, patients may develop uncomplicated mononucleosis or polyclonal polymorphic B-cell hyperplasia, both of which depend on continued viral replication. These benign PTLDs can spontaneously resolve (if host immune response to the virus is adequate) and/or respond to antiviral therapy that interrupts the EBV replicative cycle. In some patients, these benign PTLDs may progress to an intermediate stage in which a small subpopulation of malignantly transformed cells is present in a predominantly polyclonal proliferation. This second step may involve a cytogenetic event or selection that confers malignant growth potential on an EBV-infected B cell, thus leading to the outgrowth of a malignant cell or single clone analogous to the pathogenesis of African Burkitt lymphoma.
In some patients, the malignant cell clone may become the dominant proliferating cell type, leading to frank lymphoma. Tsao et al have provided a recent review of the pathological classifications and evolutions.25
Much remains to be understood about the factors involved in determining the severity of PTLD in an individual patient.
Clinical Features
Clinical features of posttransplant lymphoproliferative disease (PTLD) can be multiple, varied, and complex. In many patients, the early symptoms are nonspecific, including fever, malaise, and weight loss. Maintaining a high index of suspicion for PTLD in all transplant recipients is strongly recommended.
The most common presentation is of sudden-onset lymphoid mass swelling, either externally (eg, cervical lymph nodes) or internally (eg, abdominal or intracranial masses). Extranodal tumors are usually more common than nodal tumors. Occasionally, these masses may develop within the graft, such as the kidney or liver. The symptoms are then related to the secondary effects of the tumor, such as abdominal pain, respiratory difficulty, stridor, and seizures. CNS presentation is associated with a poorer prognosis.
PTLD may present as a fever of unknown origin in the transplant recipient or may mimic graft rejection, particularly late rejection.
The time to PTLD diagnosis posttransplant can widely vary, ranging from a few months to several years. The mean time in most series is 20-35 months, but this is skewed by the long-range interval. The median times are much shorter, approximately 4-5 months. NAPRTCS data and a report by Alfrey et al show a reduction in median time to PTLD in recent years.3,1
Diagnosis
The diagnosis of PTLD may often be complicated. Initial studies are often focused on the manifesting symptoms, such as imaging localization of the mass and determination of its extent, invasiveness, and homogenicity. Ultrasonography, CT scanning, or MRI can be used, depending on the area of interest. Pickhardt et al have published an extensive series of reviews of imaging features of PTLD by body segment.26,27,28,29,30 CT scanning is preferred for abdominal and chest imaging. Either CT scanning or MRI can be performed for neuroimaging. Bone marrow biopsies are necessary to help define marrow involvement, which may rarely be the only affected tissue. These imaging and biopsy tests may also be repeated after treatment to assess the response.
Concomitant serologic tests (ie, immunoglobulin [Ig] G and IgM) should be performed to determine recent EBV or CMV primary or secondary infection. The sera can also be analyzed for Epstein-Barr–viral capsid antigen (EB-VCA).
Histopathologic diagnosis of biopsy tissue remains the criterion standard for making the diagnosis of PTLD. Using light microscopy, infiltrates of polymorphous or monomorphous mononuclear cells (small lymphocytes and plasma cells) are observed that disrupt the architecture of the invaded tissue, such as the lymph node. Depending on the degree of proliferation and dedifferentiation, lesions may be characterized as hyperplastic, lymphomatous, or intermediate. Abnormal cells may be positive for the B-cell markers CD19, CD20, CD21, or CD22, although not in every patient. Lymphocyte CD20 expression is of value on determining therapy choices. Determination of cell surface heavy and light chain Ig expression allows for classification as polyclonal or monoclonal. Detailed cytogenetic studies may be needed in patients with nuclear changes suggestive of frank malignancy.
EBV can frequently be revealed within the abnormal cells using various methods. Epstein-Barr–encoded RNA can be detected by the Ebstein-Barr early region (EBER) immunostaining assay (see Media file 1). The EBV latent membrane protein (LMP) can also be identified through immunostaining. Some PTLDs demonstrate Reed-Sternberg–like cells that may cause confusion with Hodgkin disease; CD15 staining is typically positive in true Hodgkin disease and negative in the HD-like condition.
PTLD may occur alongside acute rejection, and the diagnoses may be difficult to separate, especially with T-cell PTLD within the allograft. According to Nalesnik, the features that favor the diagnosis of PTLD in such cases include nodular infiltrates, serpiginous necrosis, plasmacytoid and immunoblastic cells, and absence of ancillary cells such as neutrophils.31
In an effort to improve the likelihood of successful therapeutic interventions, many investigators have studied methods that may result in early identification of disease in patients at high risk for this disorder. Monoclonal proteins, particularly IgM-related proteins, have been reported to appear with greater frequency in serum and urine of patients with PTLD (71%) than in patients without PTLD (27%). Darenkov et al reported that CD19+ B cells could be detected in the peripheral blood of patients with PTLD but not in those without PTLD, provided no antiviral prophylaxis was used.32
Of greater promise are the variations of quantitative or semiquantitative polymerase chain reaction (PCR) techniques to detect EBV viral DNA from the peripheral blood lymphocytes. These techniques measure DNA in blood that can be membrane bound or free. Multiple studies have demonstrated that increased EBV viral loads can be used to differentiate between latent infection and PTLD. Rooney et al showed that levels of EBV DNA between 20,000 and 200,000 copies per microgram of peripheral blood DNA were associated with subsequent PTLD (normal <2000 copies per microgram).33
In a study by Rowe et al, an EBV genomic load greater than 500 copies per 100,000 lymphocytes was associated with PTLD development.34 Wadowsky et al (2003) have reported that whole blood or peripheral blood mononuclear amplification by competitive reverse transcriptase–PCR gives comparable results but not amplification from plasma. However, different techniques in different labs and different cut-off values between labs prevent standardization of results between those labs.
In pediatric patients, viral load monitoring is associated with high sensitivity but poor specificity. Many pediatric patients exhibit higher viral loads than adults because of a primary EBV infection or a chronic high viral load state without ever developing PTLD.35 In anecdotal cases, pediatric PTLD lesions that were EBER or LMP stain positive were not associated with a high viral load in peripheral blood.36 In contrast, Tsai et al reported that in adult transplant recipients, EBV viral load monitoring was associated with a high specificity but low sensitivity, the opposite of what has been reported in children.37 This may be related to a relatively higher prevalence of non-EBV, T-cell type or late-onset PTLD in adult patients.
Rooney et al reported that, in patients who had received bone marrow transplants, spontaneous outgrowth ex vivo of B cells transformed with EBV from the peripheral blood was associated with PTLD to a very high degree of sensitivity and specificity.33
DNA levels may also provide evidence of successful therapy. A drop in viral load after intervention suggests a good response.38 However, this may not hold true after anti-CD20 antibody, where viral loads may remain high because of release of viral DNA from lysed B cells.
Differential diagnosis
A high index of suspicion for PTLD must be maintained in all transplant recipients. Dharnidharka et al reported several cases of catscratch disease that manifested with fever and lymphadenopathy and resembled PTLD.20 The diagnosis was suspected after inquiry for cat exposures and was confirmed by (1) serological detection of IgM antibodies to Bartonella henselae and (2) detection of Bartonella species in the lesions by Steiner stain. This condition is often self-limiting in immunocompetent patients and amenable to antimicrobial therapy (sulfamethoxazole-trimethoprim, gentamicin) in immunosuppressed patients. In developing countries, tuberculosis is endemic and also manifests with fever and lymphadenopathy.
Treatment and Prophylaxis
Treatment
No uniform consensus regarding optimal treatment options for posttransplant lymphoproliferative disease (PTLD) is available. This largely reflects the current multiple gaps in knowledge of this disorder. The American Society of Transplantation and American Society of Transplant Surgeons published an ad hoc joint committee consensus paper on management recommendations; however, they recognized that providing many evidence-based recommendations is impossible.39 Thus, this paper reflects guidelines only and allows for considerable flexibility. Most centers recommend a staged treatment regimen based on the degree of clonality and aggressiveness. Treatment recommendations may rapidly change with newer understanding of the disease pathogenesis.
Reduction of immunosuppression is the first intervention recommended and should be performed in all patients. Most centers reduce the dose of calcineurin inhibitors, and many centers discontinue calcineurin inhibitors entirely if the disease is severe. Many centers also discontinue or reduce mycophenolate or azathioprine. Corticosteroids are usually continued without dosage modification. In mild cases, these steps may be the only interventions required. Graft rejection is an obvious risk but, surprisingly, is not observed in every patient. Immunomodulation by the underlying disease is speculated to prevent the normal alloimmune response in these patients.
Anti-CD20 monoclonal antibody has recently been used, with promising results, to neutralize the CD20-expressing B cells. Several small uncontrolled series have documented good success rates (complete or partial remission) in the 60-70% range in polymorphic or polyclonal cases. In some situations, the PTLD lesions may not express CD20; thus, rituximab may not be useful in such cases. This agent has become the second-line therapy at many centers, overtaking the use of interferon-alfa. Some investigators have proposed its use as first-line therapy, but no data has compared rituximab to reduction of immunosuppression head on.
Interferon-alfa is also reported to be efficacious in treatment of PTLD that is unresponsive to immunosuppressive dose reduction alone. Some protocols combine this agent with intravenous IG (IVIG) or CMV-specific Ig. Because of a higher prevalence of acute rejection episodes after interferon use, this agent is less commonly used.
The role of antiviral drugs in treatment of PTLD is controversial. Acyclovir and ganciclovir are effective against replicating the virus but are reportedly not effective against latent EBV, which is the predominant form of EBV in PTLD. However, a few virions entering the lytic cycle are possible, and antiviral agents may eliminate these virions. Many centers thus add antiviral therapy to their regimens to eliminate any replicating virus that may be present.
Standard cancer chemotherapy is reserved for patients with definitive features of malignancy. The usual regimen used has been the cyclophosphamide, doxorubicin (Adriamycin or doxorubicin hydrochloride), vincristine (Oncovin), and prednisone (CHOP) regimen used for non-Hodgkin lymphoma. Gross et al have used a modified CHOP protocol with lower doses of cyclophosphamide to prevent toxicity.40 Newer agents that have been tried in non-Hodgkin lymphoma but not tried yet in PTLD include radioconjugated anti-CD20 antibodies such as tositumomab (anti-CD20 tagged to I131) and ibritumomab (anti-CD20 tagged to Y90).
Prognosis
The prognosis of PTLD widely varies. Most mild cases regress, but graft rejection may occur (reported rates vary widely from 10-60%). The outlook for more severe cases is less favorable, particularly in frank malignancies or CNS PTLD. Although individual centers with high PTLD rates report good patient and graft survival rates, multicentered registry data suggest somewhat poorer graft survival outcomes. Non-EBV positive or late onset cases have a poorer prognosis.
In a few cases in which graft loss occurs, retransplantation has been successfully performed. To date, 3 cases of repeat kidney transplant or liver transplant have been reported.41,42,43 PTLD recurrence in the repeat transplant has not been reported.
Prophylaxis
With the role of EBV and CMV infections in the development of PTLD now established, attention has recently turned toward prevention of these infections posttransplant in an effort to reduce prevalence of PTLD. Prevention can be primary or secondary.
Primary prevention includes the following: (1) antiviral vaccine, (2) immunization minimization to prevent infection, (3) immunoprophylaxis via intravenous immunoglobulin preparations, and (4) chemoprophylaxis via antiviral drugs.
Immunization
No vaccine against EBV is currently available. A phase II trial of a gp350 glycoprotein based vaccine is currently underway in Great Britain.
Chemoprophylaxis and immunoprophylaxis
Ganciclovir and acyclovir are antiviral agents that have demonstrated efficacy against EBV and CMV. Davis et al reported in a retrospective analysis that the prevalence of PTLD appeared to be lower with the use of concomitant antiviral therapy (ie, initially IV ganciclovir, then oral acyclovir) in adult transplant recipients.44
Darenkov et al conducted a prospective trial of prophylactic antiviral agent use during antilymphocyte antibody administration to adult transplant patients.32 Using acyclovir if both donor and recipient were CMV seronegative or ganciclovir if either were seropositive, prevalence of PTLD dropped to 0.5% in their study group, compared with 3.9% in historical controls. However, Green et al were unable to document any change in PTLD prevalence in a prospective trial utilizing acyclovir.45 In their study, initial intravenous ganciclovir followed by prolonged oral acyclovir was associated with a trend towards increased PTLD and significantly higher CMV incidence. Similarly, CMV-Ig did not have any impact on EBV infection rate or PTLD rate.46
Funch et al performed a large retrospective case-control analysis that showed that ganciclovir was associated with a significant reduction in the odds ratio for PTLD (0.62; 95% CI, 0.38-1.0).47 Acyclovir was associated with a lower and nonsignificant reduction. The addition of IVIG to ganciclovir did not further reduce the PTLD rate.48
The newer oral agents, valacyclovir and valganciclovir, have greater bioavailability but have not been tested for PTLD prevalence reduction, although many centers now routinely use valganciclovir for prophylaxis. A recently published study demonstrated that oral valganciclovir is not inferior to intravenous ganciclovir for the treatment of CMV disease.49
Preemptive Interventions
Using routine viral load monitoring and preemptive therapy, several studies have shown a reduction in PTLD prevalence based on historical controls, particularly in the pediatric liver transplant population.4,32,44 These results have led many centers to perform routine viral load monitoring, particularly for preemptive interventions. These interventions have included reduction in immunosuppression or initiation of antiviral therapy when a significant rise in EB viral load occurs. To date, no prospective clinical trials have been performed to confirm these results, but these types of studies are difficult to perform. The hypothesis that early detection leads to improved outcome remains also remains to be confirmed. Wagner et al have suggested that prompt invention rather than preemptive intervention may be a better strategy in combination with viral load monitoring.50
Viral load monitoring provides evidence of EBV-infected B-cell proliferation but does not provide information about the host T-cell response. Studies of EBV-specific T-cell counts or cytotoxic T-cell assays may add further information to EBV viral loads.51
Summary and Future Directions
Posttransplant lymphoproliferative disease (PTLD) is a complex and puzzling entity that is now a significant complication of solid organ transplantation. Prevalence is still rising in many centers, and the outlook varies. Etiology is related to EBV infection of B cells, which cannot be controlled by cytotoxic T cells because of external immunosuppression that is required to prevent graft rejection. Clinical features can vary. Lymphoid masses are the most common manifesting features. Imaging and serologic tests provide supportive data, but histopathology is required for a definitive diagnosis. Treatment options include reduction of immunosuppression, anti-CD20 monoclonal antibody, alpha-interferon, and chemotherapy. Antiviral prophylaxis and early detection measures now are being used to prevent the disease and improve outcome.
Multimedia
 | Media file 1: Epstein-Barr viral RNA can be detected by Epstein-Barr early region (EBER) assay (dark-blue staining cells) in the abnormal B cells from tumor masses of posttransplant lymphoproliferative disease (PTLD). |
Keywords
posttransplant lymphoproliferative disorder, PTLD, posttransplant lymphoproliferative disease, lymphoproliferative disorder, LPD, Epstein-Barr virus, EBV, cytomegalovirus, CMV, posttransplant immunosuppression, B cells, solid organ transplantation complication, B-cell proliferation, B cell proliferation, liver transplant, intestinal transplantation, heart transplant, lung transplant, bone marrow transplant, immunosuppression regimens, cyclosporine, CsA, muromonab-Cd3, OKT3, tacrolimus, FK506, common variable immunodeficiency, Wiskott-Aldrich syndrome, ataxia telangiectasia, severe combined immunodeficiency, acquired immunodeficiency syndrome, AIDS, mononucleosis, polyclonal polymorphic B-cell hyperplasia, African Burkitt lymphoma, frank lymphoma
More on Posttransplant Lymphoproliferative Disease |
| References |
References
Alfrey EJ, Friedman AL, Grossman RA, et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder. Transplantation. Aug 1992;54(2):250-3. [Medline].
Ciancio G, Siquijor AP, Burke GW, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant. Jun 1997;11(3):243-9. [Medline].
Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation. Apr 27 2001;71(8):1065-8. [Medline].
McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. Dec 27 1998;66(12):1604-11. [Medline].
Brennan DC, Schnitzler MA, Ceriotti C, et al. The Barnes-Jewish Hospital/Washington University Renal Transplant Program: comparison of two eras 1991-1994 and 1995-2000. Clin Transpl. 2001;131-41. [Medline].
Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. Nov 2002;2(10):993-8. [Medline].
Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant. Mar-Apr 1995;14(2):214-21. [Medline].
Manez R, Breinig MK, Linden P, et al. Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl Int. 1994;7 Suppl 1:S235-7. [Medline].
McGeown MG, Douglas JF, Middleton D. One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre. Clin Transpl. 2000;193-202. [Medline].
Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. Dec 20 1990;323(25):1723-8. [Medline].
Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation. Feb 27 1995;59(4):524-9. [Medline].
Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation. Nov 27 1997;64(10):1438-42. [Medline].
Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation. Aug 15 1996;62(3):370-5. [Medline].
Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. Apr 2000;7(2):147-56. [Medline].
Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant. Feb 1998;2(1):56-63. [Medline].
Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005;(4):CD003961. [Medline].
Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. Oct 8 2005;331(7520):810. [Medline].
Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. Nov 15 2003;76(9):1289-93. [Medline].
Funch DP, Ko HH, Travasso J, et al. Association between mycophenolate mofetil and development of posttransplant lymphoproliferative disorder in renal transplant patients in the U.S. Am J Transplant. 2003;5 (Suppl 5):763A.
Dharnidharka VR, Richard GA, Neiberger RE, Fennell RS 3rd. Cat scratch disease and acute rejection after pediatric renal transplantation. Pediatr Transplant. Aug 2002;6(4):327-31. [Medline].
Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. Jan 2004;4(1):87-93. [Medline].
Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. Dec 18-25 1993;342(8886-8887):1514-6. [Medline].
Babel N, Vergopoulos A, Trappe RU, Oertel S, Hammer MH, Karaivanov S. Evidence for Genetic Susceptibility Towards Development of Posttransplant Lymphoproliferative Disorder in Solid Organ Recipients. Transplantation. Aug 15 2007;84(3):387-391. [Medline].
Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. Dec 1999;17(12):3835-49. [Medline].
Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med. Aug 2007;131(8):1209-18. [Medline].
Pickhardt PJ, Siegel MJ. Abdominal manifestations of posttransplantation lymphoproliferative disorder. AJR Am J Roentgenol. Oct 1998;171(4):1007-13. [Medline].
Pickhardt PJ, Siegel MJ. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology. Oct 1999;213(1):73-8. [Medline]. [Full Text].
Pickhardt PJ, Siegel MJ, Anderson DC, et al. Chest radiography as a predictor of outcome in posttransplantation lymphoproliferative disorder in lung allograft recipients. AJR Am J Roentgenol. Aug 1998;171(2):375-82. [Medline].
Pickhardt PJ, Siegel MJ, Hayashi RJ, Kelly M. Posttransplantation lymphoproliferative disorder in children: clinical, histopathologic, and imaging features. Radiology. Oct 2000;217(1):16-25. [Medline]. [Full Text].
Pickhardt PJ, Wippold FJ 2nd. Neuroimaging in posttransplantation lymphoproliferative disorder. AJR Am J Roentgenol. Apr 1999;172(4):1117-21. [Medline].
Nalesnik MA. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol. 1998;20(3-4):325-42. [Medline].
Darenkov IA, Marcarelli MA, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation. Sep 27 1997;64(6):848-52. [Medline].
Rooney CM, Loftin SK, Holladay MS, et al. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. Jan 1995;89(1):98-103. [Medline].
Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol. Jun 1997;35(6):1612-5. [Medline]. [Full Text].
Green M, Webber S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am. Dec 2003;50(6):1471-91. [Medline].
Axelrod DA, Holmes R, Thomas SE, Magee JC. Limitations of EBV-PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder. Pediatr Transplant. Jun 2003;7(3):223-7. [Medline].
Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. Apr 27 2001;71(8):1076-88. [Medline].
Baiocchi OC, Colleoni GW, Caballero OL, et al. Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort. Haematologica. Mar 2004;89(3):366-8. [Medline].
Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. Oct 2000;11 Suppl 15:S1-86. [Medline].
Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol. Sep 20 2005;23(27):6481-8. [Medline].
Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?. Transplantation. Sep 27 2003;76(6):984-8. [Medline].
Karras A, Thervet E, Le Meur Y, et al. Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant. Nov 2004;4(11):1904-9. [Medline].
Grant W, Horslen SP, Botha JF, et al. Posttransplant lymphoproliferative disorder following pediatric liver transplantation; long-term patient and graft survival. Pediatr Transplantation. 2003;7 (Suppl 4):282A.
Davis CL, Harrison KL, McVicar JP. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant. Feb 1995;9(1):53-9. [Medline].
Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis. Dec 1997;25(6):1344-9. [Medline].
Green M, Michaels MG, Katz BZ, Burroughs M, Gerber D, Shneider BL. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant. Aug 2006;6(8):1906-12. [Medline].
Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. Dec 2005;5(12):2894-900. [Medline].
Humar A, Hebert D, Davies HD, Humar A, Stephens D, O'Doherty B. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation. Mar 27 2006;81(6):856-61. [Medline].
Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. Sep 2007;7(9):2106-13. [Medline].
Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. May 15 2004;103(10):3979-81. [Medline]. [Full Text].
Baudouin V, Dehee A, Pedron-Grossetete B, et al. Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study. Transplantation. Jun 15 2004;77(11):1706-13. [Medline].
Boyle GJ, Michaels MG, Webber SA, et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr. Aug 1997;131(2):309-13. [Medline].
Chadburn A, Chen JM, Hsu DT, et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer. May 15 1998;82(10):1978-87. [Medline].
Dharnidharka VR, Harmon WE. Infections post transplantation. In: Pediatric Solid Organ Transplantation. 2000:135-52.
Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant. Oct 2002;6(5):396-9. [Medline].
Dharnidharka VR, Tejani AH. Immunosuppression of pediatric kidney transplant recipients: minimizing the risk of PTLD. Transplantation and Immunology Letter. 1998;14:3-12.
Dror Y, Greenberg M, Taylor G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation. Apr 15 1999;67(7):990-8. [Medline].
Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation. Oct 15 1999;68(7):997-1003. [Medline].
Glez-Chamorro A, Jimenez C, Moreno-Glez E, et al. Management and outcome of liver recipients with post-transplant lymphoproliferative disease. Hepatogastroenterology. Jan-Feb 2000;47(31):211-9. [Medline].
Green M, Michaels MG, Webber SA, et al. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transplant. Nov 1999;3(4):271-81. [Medline].
Green M, Webber SA. EBV viral load monitoring: unanswered questions. Am J Transplant. Nov 2002;2(10):894-5. [Medline].
Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med. 1995;46:381-94. [Medline].
Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med. Apr 15 1982;306(15):913-8. [Medline].
Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res. Nov 1981;41(11 Pt 1):4253-61. [Medline].
Harmon WE, Dharnidharka VR. Lymphoproliferative disease in children. Transplant Proc. Feb-Mar 1999;31(1-2):1268-9. [Medline].
Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol. Feb 1997;14(1):8-14. [Medline].
Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis. Nov 1985;152(5):876-86. [Medline].
Jain A, Mazariegos G, Kashyap R, et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation. Aug 27 2000;70(4):617-25. [Medline].
Kenagy DN, Schlesinger Y, Weck K, et al. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation. Sep 27 1995;60(6):547-54. [Medline].
Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. Jan 15 1995;85(2):552-65. [Medline]. [Full Text].
Kopf S, Tonshoff B. Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients. Pediatr Nephrol. Apr 2004;19(4):365-8. [Medline].
Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol. Apr 1995;13(4):961-8. [Medline].
Nalesnik M, Jaffe R, Reyes J, et al. Posttransplant lymphoproliferative disorders in small bowel allograft recipients. Transplant Proc. Sep 2000;32(6):1213. [Medline].
Nocera A, Ghio L, Dall'Amico R, et al. De novo cancers in paediatric renal transplant recipients: a multicentre analysis within the North Italy Transplant programme (NITp), Italy. Eur J Cancer. Jan 2000;36(1):80-6. [Medline].
Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. Nov 27 1999;68(10):1517-25. [Medline].
Praghakaran K, Wise B, Chen A, et al. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg. Jan 1999;34(1):112-5; discussion 115-6. [Medline].
Qu L, Green M, Webber S, et al. Epstein-barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis. Oct 2000;182(4):1013-21. [Medline].
Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med. Dec 10 1992;327(24):1710-4. [Medline].
Savoie A, Perpete C, Carpentier L, et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood. May 1 1994;83(9):2715-22. [Medline]. [Full Text].
Scheenstra R, Verschuuren EA, de Haan A. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl Infect Dis. Mar 2004;6(1):15-22. [Medline].
Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. Dec 27 1999;68(12):1851-4. [Medline].
Shapiro RS, Chauvenet A, McGuire W, et al. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med. May 19 1988;318(20):1334. [Medline].
Smets F, Vajro P, Cornu G, et al. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation. Mar 15 2000;69(5):982-4. [Medline].
Srivastava T, Zwick DL, Rothberg PG, Warady BA. Posttransplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol. Nov 1999;13(9):748-54. [Medline].
Swinnen LJ. Transplantation-related lymphoproliferative disorder: a model for human immunodeficiency virus-related lymphomas. Semin Oncol. Aug 2000;27(4):402-8. [Medline].
Vajro P, Lucariello S, Migliaro F, et al. Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease. J Infect Dis. Jun 2000;181(6):2050-4. [Medline].
Wadowsky RM, Laus S, Green M. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol. Nov 2003;41(11):5245-9. [Medline]. [Full Text].
Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation. Jul 15 2000;70(1):94-9. [Medline].
Further Reading
Keywords
posttransplant lymphoproliferative disorder, PTLD, posttransplant lymphoproliferative disease, lymphoproliferative disorder, LPD, Epstein-Barr virus, EBV, cytomegalovirus, CMV, posttransplant immunosuppression, B cells, solid organ transplantation complication, B-cell proliferation, B cell proliferation, liver transplant, intestinal transplantation, heart transplant, lung transplant, bone marrow transplant, immunosuppression regimens, cyclosporine, CsA, muromonab-Cd3, OKT3, tacrolimus, FK506, common variable immunodeficiency, Wiskott-Aldrich syndrome, ataxia telangiectasia, severe combined immunodeficiency, acquired immunodeficiency syndrome, AIDS, mononucleosis, polyclonal polymorphic B-cell hyperplasia, African Burkitt lymphoma, frank lymphoma
